Stock pick for tomorrow, January 8, 2010 is
(CYCC: 2.35 0.00%)

They released a huge news today that Cyclacel’s Seliciclib drug candidate was found effective against Lung Cancer Cell Lines Including K-RAS Mutations.

After the news today, the shares of CYCC more than doubled. The volume was massive and this could be a real winner tomorrow.

Here is more about the news:

Cyclacel Pharmaceuticals (CYCC Quote) shares more than doubled in price Thursday on a massive spike in volume after the company’s seliciclib drug candidate was found effective against lung cancer cell lines, including K-RAS protein mutations.
Cyclacel Pharma said two peer-reviewed journal articles have been published featuring seliciclib, an orally available inhibitor of multiple cyclin-dependent kinases, or CDKs. In an article published in Clinical Cancer Research, seliciclib was found to be effective in killing lung cancer cells through an induction of cancer cell suicide. Nearly all lung cancer cell lines against which seliciclib was most effective had Ras-activating mutations, the article said.

A second peer-reviewed article published in The Journal of Cell Biochemistry said that seliciclib was found to be the most effective at inducing programmed cell death in malignant cells while resulting in significantly less apoptosis induction in normal peripheral blood mononuclear cells, “suggesting the largest therapeutic window among the treatments studied.”

“We look forward to unblinding data from our completed Phase 2, randomized, double-blinded…trial in patients with pretreated [non-small cell lung cancer] during 2010,” said Professor David Glover, Ph.D., Cyclacel’s Chief Scientist. “If seliciclib is found to be effective in patients with Ras-mutant [non-small cell lung cancer], it could address an area of high unmet medical need.”

Source